Dr. Reddy's Reports Q3 FY26 Profitability Decline and USFDA Denosumab Biosimilar CRL

summarizeSummary

Dr. Reddy's Laboratories reported Q3 FY26 results with modest revenue growth but a significant decline in diluted EPS and EBITDA margins year-over-year, alongside a Complete Response Letter from the USFDA for its denosumab biosimilar.

check_boxKey Events

• Q3 FY26 Financial Performance

  Revenues grew 4.4% year-over-year to ₹8,727 Cr, but diluted EPS declined 14% to ₹14.5, and EBITDA margin decreased to 23.5% from 27.5% in the prior year.

• Regulatory Setback for Denosumab Biosimilar

  The company received a Complete Response Letter (CRL) from the USFDA for its denosumab biosimilar BLA, citing observations at Alvotech's facility.

• USFDA Observations

  An inspection at the FTO-SEZ PU-01 formulations facility resulted in five Form 483 observations, though a response has been submitted.

• Strategic Collaboration

  Dr. Reddy's entered a strategic collaboration with Immutep for the commercialization of an oncology drug, Eftilagimod Alfa, in key Emerging Markets, including an upfront payment of US$20 million and potential milestones up to US$350 million.

auto_awesomeAnalysis

Dr. Reddy's Laboratories' Q3 FY26 results indicate a challenging quarter with declining profitability metrics despite modest revenue growth. The significant year-over-year drop in diluted EPS and EBITDA margins, coupled with product-specific headwinds and pricing pressure in North America, suggests operational challenges. The Complete Response Letter from the USFDA for the denosumab biosimilar is a notable setback, delaying a key product's market entry. While new product launches and a strategic collaboration offer future potential, the immediate financial performance and regulatory hurdles present a negative outlook for investors.